Vasotec Articles
Candesartan CHF Trial Stopped On Mortality Concerns
24 November 1997
Greek Govt Adjusts Prices Of 6,009 Drugs
3 October 1997
2005 US CHF Market: 27% Angiotensin II Antagonists
6 August 1997
Antihypertensive Sales "Set To Decline"
1 August 1997
Older Antihypertensives As Good As The New
24 July 1997
First Approval Of SB's Teveten, In Germany
9 June 1997
Richter Gedeon: Independent And Profitable
5 May 1997
US Launch For Novartis' Valsartan
10 March 1997
Currency Exchange Affects 1996 Sales At Astra
24 February 1997
FDA Year-End Approval Spate As Expected
6 January 1997
Astra's Losec "World's No One Drug In 1998-2000"
16 December 1996
HMR's Teczem In USA
11 November 1996
US Drug Majors See 2nd-Half Double-Digit Growth
29 July 1996
Encouraging HOT Study Results
8 July 1996
World Pharma Market Growth 11.6% In 1995
27 May 1996
US Firms' Strong 1st Qtr Lifts Share Prices
29 April 1996
- Candesartan Cilexetil Submissions By Fall 1996
22 April 1996
Japanese Price Cuts: The Myths And Realities
15 April 1996
Premarin Heads Top-10 Prescription Drugs
1 April 1996
Corporate Ranking - A New Order For 1995
1 April 1996
Drug Firms, HMOs And The Battle To Set US Prices
25 March 1996
World Pharma Sales Up 11.6% In 1995, Says PMSI
18 March 1996
Sweden's Pharma Market Expanded 12.7% In 1995
4 March 1996
Losec "Will Be The World's Top-Selling Drug In 2000"
26 February 1996
World Markets: Cancer, Cardiovascular, Menopause
19 February 1996
FDA Panel Verdict On Calcium Blockers
5 February 1996
All Change For Top Drugs In Year 2000: Lehman Bros
15 January 1996
Astra Strengthens R&D With Increased Spending
4 December 1995
US Drug Cos Reveal Strong Growth In 1995 3rd Qtr
30 October 1995
ACE inhibitor/aspirin interaction?
23 October 1995
Calcium Blockers In HF: V-HeFT III & DEFIANT II
4 September 1995
US Sales of Generic Drugs Up 29% In 1994, Says IMS
17 July 1995
The Drug Industry And The Nafta Experience
10 July 1995
Drug Industry Growth Held Back In Dominican republic
26 June 1995
Disease ManagementThe Way Forward
15 May 1995
....And Marion Merrell Dow Updates On R&D Efforts
10 April 1995
Losec Europe's Top-Selling Product
10 April 1995
20 Leading US Drugs' Price Increases Slammed
27 March 1995
Hoechst Offers $7 Billion For Marion Merrell Dow
6 March 1995
IMS Studies US Retail Drug Payments
16 January 1995
$25 Bill Latin American Pharma Market In 2000
9 January 1995
Apotex' Enalapril Taken Off Market In Canada
2 January 1995
South African Pharma Market $4 Billion In 2002
21 November 1994
Astra's Logimax Versus Enalapril
14 November 1994
Astra Merck: New Stand-Alone Company
7 November 1994
Astra's Logimax Could Be First-Line Therapy
7 November 1994
USA's Top-Selling Drugs In 1993
24 October 1994
Canada: Province's "Secret Pact With Drug Firms"
24 October 1994
DDT's New Global Pharma Market Review 1994
10 October 1994
Enalapril And Non-Diabetic Renal Failure
10 October 1994
Benefits From PBM/MPC Acquisitions Assessed
15 August 1994
Strong Gains By US Firms In 2nd Quarter
1 August 1994
ANTIHYPERTENSIVES FAIL TROUGH-PEAK CRITERIA
20 June 1994
APO-ENALAPRIL IN ALBERTA
9 May 1994
MERCK & CO POSTS 10% PR0FIT RISE
25 April 1994
ACTISITE CLEARED FOR MARKET IN USA
11 April 1994
ZENECA'S PIPELINE ON TARGET AS TENORMIN SLIPS
14 March 1994
N AMERICAN PHARMA MARKET STUDIED
28 February 1994
SWEDISH PHARMA MARKET GROWTH SLOWDOWN
28 February 1994
CAPOTEN GAINS ADDITIONAL LICENSE IN UK
21 February 1994
APOTEX BATTLES ON IN COURT
7 February 1994
ISRAEL'S PRESCRIPTION DRUG MARKET
31 January 1994
LIKELY IMPACT ON DRUG FIRMS OF ITALIAN REFORMS
17 January 1994
DRUGMAKERS IN ITALY PANIC ON NEW SALES FEARS
10 January 1994
ENALAPRIL GETS POST-MI INDICATION
22 November 1993
NEW YORK STOCK COMMENT
15 November 1993
ACCUPRIL APPROVED FOR CHF INDICATION
15 November 1993
ACE INHIBITORS POST-MI: THE PRACTICAL STUDY
15 November 1993
APOTEX WINS ROUND IN ENALAPRIL DISPUTE
1 November 1993
US 3rd QTR RESULTS MIXED AS DRUG IND CUTS BACK
25 October 1993
SALT DERIVATIVE BENEFITS
4 October 1993
MERCK AND APOTEX DISPUTE CONTINUES
13 September 1993
ZESTRIL APPROVED FOR GP INITIATION
6 September 1993
APOTEX WINS ENALAPRIL DECISION
6 September 1993
RESULTS OF AIRE STUDY SHOW ACE INHIB BENEFIT
6 September 1993
US DRUGSTORE AUDIT DATA FOR JULY
6 September 1993
DRUG THERAPY FOR MILD HYPERTENSION FAVORED
16 August 1993
GENERIC ENALAPRIL SOON IN CANADA?
2 August 1993
ALZA CONFIRMS ITS DRUGS WERE LICENSED TO MERCK
12 July 1993
FAVORABLE TOXICITY FOR TANAPRIL
5 July 1993
MMD LICENSES TWO MERCK DRUGS
28 June 1993
VASOTEC AND DIABETES
28 June 1993
ZESTRIL APPROVED FOR CHF IN USA
21 June 1993
US DRUGMAKERS AND "THE BLACK HOLE"
21 June 1993
BOOTS' FLOSEQUINAN IN FURTHER TROUBLE?
14 June 1993
ENALAPRIL - A NEW HOPE FOR DIABETICS?
24 May 1993
SOLVD TRIAL RESULTS
19 April 1993
ACE INHIBITOR STUDY
19 April 1993
US PRESCRIPTION DRUG PRICES GOING DOWN
12 April 1993
SWEDEN'S PHARMA MARKET IN 1992
5 April 1993
FDA PANEL ADVISES ON ACE INHIBITOR DRUGS
1 March 1993
MERCK CANADA MOVES TO WARD OFF COMPETITION
1 March 1993
LISINOPRIL BETTER THAN ENALAPRIL?
8 February 1993
RECORD RESULTS FROM US PHARMA MAJORS
1 February 1993
FIRST LAUNCH OF ROUSSEL UCLAF'S TRANDOLAPRIL
25 January 1993
STAGE SET FOR C-91 TO GO BEFORE CANADA'S SENATE
18 January 1993
GLOBAL DRUG MARKET: 30 YEARS OF GROWTH
4 January 1993
MERCK & CO EARNINGS ESTIMATES LOWERED
14 December 1992
ANTIHYPERTENSIVES IN DIABETICS
2 November 1992
- Elan makes "transformational" acquisitions and a divestment
- Drug prices to plunge as Indian government announces plans to regulate rates of 652 medicines
- SciClone gains China rights to Zensun's Neucardin
- Bristol-Myers' data on Yervoy and nivolumab causes a stir
- HIV vaccines: small biotech and government-funded organizations will step in where Big Pharma has fallen short, says analyst
